SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001493152-22-030819
Filing Date
2022-11-07
Accepted
2022-11-07 16:05:55
Documents
60
Period of Report
2022-09-30

Document Format Files

Seq Description Document Type Size
1 form10-q.htm   iXBRL 10-Q 994723
2 ex10-1.htm EX-10.1 18561
3 ex31-1.htm EX-31.1 18631
4 ex31-2.htm EX-31.2 16725
5 ex32-1.htm EX-32.1 6938
6 ex32-2.htm EX-32.2 6902
  Complete submission text file 0001493152-22-030819.txt   4232015

Data Files

Seq Description Document Type Size
7 XBRL SCHEMA FILE ltrn-20220930.xsd EX-101.SCH 32157
8 XBRL CALCULATION FILE ltrn-20220930_cal.xml EX-101.CAL 45242
9 XBRL DEFINITION FILE ltrn-20220930_def.xml EX-101.DEF 106794
10 XBRL LABEL FILE ltrn-20220930_lab.xml EX-101.LAB 263988
11 XBRL PRESENTATION FILE ltrn-20220930_pre.xml EX-101.PRE 206590
54 EXTRACTED XBRL INSTANCE DOCUMENT form10-q_htm.xml XML 567006
Mailing Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201
Business Address 1920 MCKINNEY AVENUE 7TH FLOOR DALLAS TX 75201 972-277-1136
Lantern Pharma Inc. (Filer) CIK: 0001763950 (see all company filings)

IRS No.: 463973463 | State of Incorp.: TX | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-39318 | Film No.: 221365404
SIC: 2834 Pharmaceutical Preparations